Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Adamson

Showing results (271-280 of 342) with videos related to

Pageof 35
Sort By:
Clinical Pharmacology and Therapeutics|June 14, 2023
Model-Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence EpilepsyKana Mizuno, Edmund V Capparelli, Tsuyoshi Fukuda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2012
A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium reportJulia Glade Bender, Susan M Blaney, Scott Borinstein, et al.
Neurology|May 31, 2013
Pretreatment EEG in childhood absence epilepsy: associations with attention and treatment outcomeDennis Dlugos, Shlomo Shinnar, Avital Cnaan, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2004
Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101P C Adamson, S M Blaney, B C Widemann, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2008
Pharmacokinetics and safety of caspofungin in older infants and toddlersMichael Neely, Hasan S Jafri, Nita Seibel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2007
Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology GroupSuman Malempati, H Stacy Nicholson, Joel M Reid, et al.
Pediatric Blood & Cancer|June 20, 2020
Pediatric cancer research: Surviving COVID-19Jeffery J Auletta, Peter C Adamson, Jonathan E Agin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2007
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group StudyTerzah M Horton, Patrick A Thompson, Stacey L Berg, et al.
Pharmacoepidemiology and Drug Safety|May 4, 2012
Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology GroupR Aplenc, B T Fisher, Y S Huang, et al.
Pediatric Blood & Cancer|July 21, 2006
Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942)Shana S Jacobs, Linda C Stork, Bruce C Bostrom, et al.
Pageof 35

Showing results (271-280 of 342) with videos related to

Sort By:
Pageof 35
Clinical Pharmacology and Therapeutics|June 14, 2023
Model-Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence EpilepsyKana Mizuno, Edmund V Capparelli, Tsuyoshi Fukuda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2012
A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium reportJulia Glade Bender, Susan M Blaney, Scott Borinstein, et al.
Neurology|May 31, 2013
Pretreatment EEG in childhood absence epilepsy: associations with attention and treatment outcomeDennis Dlugos, Shlomo Shinnar, Avital Cnaan, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2004
Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101P C Adamson, S M Blaney, B C Widemann, et al.
Antimicrobial Agents and Chemotherapy|December 31, 2008
Pharmacokinetics and safety of caspofungin in older infants and toddlersMichael Neely, Hasan S Jafri, Nita Seibel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2007
Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology GroupSuman Malempati, H Stacy Nicholson, Joel M Reid, et al.
Pediatric Blood & Cancer|June 20, 2020
Pediatric cancer research: Surviving COVID-19Jeffery J Auletta, Peter C Adamson, Jonathan E Agin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2007
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group StudyTerzah M Horton, Patrick A Thompson, Stacey L Berg, et al.
Pharmacoepidemiology and Drug Safety|May 4, 2012
Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology GroupR Aplenc, B T Fisher, Y S Huang, et al.
Pediatric Blood & Cancer|July 21, 2006
Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942)Shana S Jacobs, Linda C Stork, Bruce C Bostrom, et al.
Pageof 35